Insilico Initiates Phase III Clinical Trial for Rentosertib, Its AI-Empowered TNIK Inhibitor for Idiopathic Pulmonary Fibrosis

Insilico Initiates Phase III Clinical Trial for Rentosertib, Its AI-Empowered TNIK Inhibitor for Idiopathic Pulmonary Fibrosis

PR Newswire

CAMBRIDGE, Mass., July 7, 2026

Potentially first-in-class oral TNIK inhibitor advances into late-stage development after milestones marked by vital peer-reviewed papers: the discovery-to-clinic journey in Nature Biotechnology, and positive Phase IIa clinical results in Nature MedicineRentosertib represents a novel mechanism, novel AI-identified target, and novel AI-empowered molecule emerging from Insilico's aging-biology-driven Pharma.AI platformThe GENESIS-IPF Phase IIa study showed manageable safety and tolerability, with the 60 mg once-daily arm demonstrating mean forced vital capacity improvement of +98.4 mL at 12 weeksCAMBRIDGE, Mass., July 7, 2026 /PRNewswire/ -- Insilico Medicine ("Insilico," HKEX: 3696), a clinical-stage biotechnology company powered by generative AI, today announced the initiation of the Phase III clinical trial for Rentosertib, its potentially first-in-class oral small-molecule inhibitor targeting TNIK for the treatment of idiopathic pulmonary fibrosis (IPF), a progressive, age-related fibrotic lung disease with high unmet medical need.